...
search icon
omer-img

Omeros Corporation, Common Stock

OMER

NASDAQ

$9.18

+$0.06

(0.66%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$531.98M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
420.29K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.48
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.61 L
$13.6 H
$9.18

About Omeros Corporation, Common Stock

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameOMERSectorS&P500
1-Week Return6.13%-0.03%1.53%
1-Month Return6.87%4.56%4.75%
3-Month Return32.09%1.29%2.77%
6-Month Return123.36%-3.54%12.18%
1-Year Return100.44%1.59%22.34%
3-Year Return47.12%13.55%38.91%
5-Year Return-30.03%40.85%80.7%
10-Year Return-57.38%105.52%190.95%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue111.81M73.81M90.52M--[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":66.02,"profit":true},{"date":"2021-12-31","value":80.96,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue865.00K902.00K1.39M952.00K69.78M[{"date":"2019-12-31","value":1.24,"profit":true},{"date":"2020-12-31","value":1.29,"profit":true},{"date":"2021-12-31","value":1.99,"profit":true},{"date":"2022-12-31","value":1.36,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit110.94M72.91M(1.39M)(952.00K)(69.78M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":65.72,"profit":true},{"date":"2021-12-31","value":-1.25,"profit":false},{"date":"2022-12-31","value":-0.86,"profit":false},{"date":"2023-12-31","value":-62.9,"profit":false}]
Gross Margin99.23%98.78%(1.53%)(Infinity%)(Infinity%)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":99.55,"profit":true},{"date":"2021-12-31","value":-1.54,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}]
Operating Expenses174.32M183.51M173.62M163.39M94.75M[{"date":"2019-12-31","value":94.99,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":94.61,"profit":true},{"date":"2022-12-31","value":89.03,"profit":true},{"date":"2023-12-31","value":51.63,"profit":true}]
Operating Income(63.38M)(110.60M)(173.62M)(163.39M)(164.53M)[{"date":"2019-12-31","value":-6338200000,"profit":false},{"date":"2020-12-31","value":-11060100000,"profit":false},{"date":"2021-12-31","value":-17361700000,"profit":false},{"date":"2022-12-31","value":-16338900000,"profit":false},{"date":"2023-12-31","value":-16453000000,"profit":false}]
Total Non-Operating Income/Expense(43.76M)(66.22M)(37.60M)(37.28M)(27.17M)[{"date":"2019-12-31","value":-4376100000,"profit":false},{"date":"2020-12-31","value":-6622200000,"profit":false},{"date":"2021-12-31","value":-3759800000,"profit":false},{"date":"2022-12-31","value":-3728000000,"profit":false},{"date":"2023-12-31","value":-2716800000,"profit":false}]
Pre-Tax Income(84.49M)(150.07M)(191.55M)(182.03M)(174.92M)[{"date":"2019-12-31","value":-8448600000,"profit":false},{"date":"2020-12-31","value":-15007200000,"profit":false},{"date":"2021-12-31","value":-19154600000,"profit":false},{"date":"2022-12-31","value":-18202900000,"profit":false},{"date":"2023-12-31","value":-17492000000,"profit":false}]
Income Taxes22.42M(12.01M)(365.76M)(210.81M)(57.11M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-53.57,"profit":false},{"date":"2021-12-31","value":-1631.39,"profit":false},{"date":"2022-12-31","value":-940.26,"profit":false},{"date":"2023-12-31","value":-254.71,"profit":false}]
Income After Taxes(106.91M)(138.06M)174.21M28.78M(117.81M)[{"date":"2019-12-31","value":-61.37,"profit":false},{"date":"2020-12-31","value":-79.25,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":16.52,"profit":true},{"date":"2023-12-31","value":-67.63,"profit":false}]
Income From Continuous Operations(84.49M)(138.06M)(191.55M)(182.03M)(181.68M)[{"date":"2019-12-31","value":-8448600000,"profit":false},{"date":"2020-12-31","value":-13806100000,"profit":false},{"date":"2021-12-31","value":-19154600000,"profit":false},{"date":"2022-12-31","value":-18202900000,"profit":false},{"date":"2023-12-31","value":-18168100000,"profit":false}]
Income From Discontinued Operations385.78M385.78M385.78M229.45M-[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":59.48,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(106.91M)(138.06M)194.24M28.78M(117.81M)[{"date":"2019-12-31","value":-55.04,"profit":false},{"date":"2020-12-31","value":-71.08,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":14.82,"profit":true},{"date":"2023-12-31","value":-60.65,"profit":false}]
EPS (Diluted)(1.70)(2.40)(1.76)0.75(1.88)[{"date":"2019-12-31","value":-226.67,"profit":false},{"date":"2020-12-31","value":-320,"profit":false},{"date":"2021-12-31","value":-234.67,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-250.67,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

OMER
Cash Ratio 2.21
Current Ratio 2.96

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

OMER
ROA (LTM) -26.87%
ROE (LTM) -576.33%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

OMER
Debt Ratio Lower is generally better. Negative is bad. 1.49
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.49

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

OMER
Trailing PE NM
Forward PE NM
P/S (TTM) 4.93
P/B 8.44
Price/FCF NM
EV/R 8.26
EV/Ebitda NM
PEG NM

FAQs

What is Omeros Corporation share price today?

Omeros Corporation (OMER) share price today is $9.18

Can Indians buy Omeros Corporation shares?

Yes, Indians can buy shares of Omeros Corporation (OMER) on Vested. To buy Omeros Corporation from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in OMER stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Omeros Corporation be purchased?

Yes, you can purchase fractional shares of Omeros Corporation (OMER) via the Vested app. You can start investing in Omeros Corporation (OMER) with a minimum investment of $1.

How to invest in Omeros Corporation shares from India?

You can invest in shares of Omeros Corporation (OMER) via Vested in three simple steps:

  • Click on Sign Up or Invest in OMER stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Omeros Corporation shares
What is Omeros Corporation 52-week high and low stock price?

The 52-week high price of Omeros Corporation (OMER) is $13.6. The 52-week low price of Omeros Corporation (OMER) is $2.61.

What is Omeros Corporation price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Omeros Corporation (OMER) is 8.44

What is the Market Cap of Omeros Corporation?

The market capitalization of Omeros Corporation (OMER) is $531.98M

What is Omeros Corporation’s stock symbol?

The stock symbol (or ticker) of Omeros Corporation is OMER

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top